$0.69
6.24% yesterday
Nasdaq, Nov 12, 10:03 pm CET
ISIN
US0044461004
Symbol
ACET

Adicet Bio Inc Stock price

$0.69
-0.29 29.90% 1M
-0.03 4.79% 6M
-0.28 28.64% YTD
-0.51 42.79% 1Y
-20.05 96.69% 3Y
-11.79 94.50% 5Y
-117.47 99.42% 10Y
-117.47 99.42% 20Y
Nasdaq, Closing price Wed, Nov 12 2025
+0.04 6.24%
ISIN
US0044461004
Symbol
ACET
Industry

Key metrics

Basic
Market capitalization
$99.0m
Enterprise Value
$-25.9m
Net debt
positive
Cash
$125.0m
Shares outstanding
83.3m
Valuation (TTM | estimate)
P/E
- | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
0.3
P/B
0.7
Financial Health
Equity Ratio
84.7%
Return on Equity
-62.7%
ROCE
-
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
- | $0.0
EBITDA
- | $-176.5m
EBIT
- | $-120.7m
Net Income
- | $-94.2m
Free Cash Flow
$-100.5m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
- | -45.2%
EBIT
- | 5.7%
Net Income
- | 19.5%
Free Cash Flow
-8.9%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
-
FCF per Share
$-1.2
Short interest
5.6%
Employees
152
Rev per Employee
$0.0
Show more

Is Adicet Bio Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,033 stocks worldwide.

Adicet Bio Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Adicet Bio Inc forecast:

12x Buy
86%
2x Hold
14%

Analyst Opinions

14 Analysts have issued a Adicet Bio Inc forecast:

Buy
86%
Hold
14%

Financial data from Adicet Bio Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 28 28
5% 5%
-
- Research and Development Expense - -
-
-
-120 -120
16% 16%
-
- Depreciation and Amortization 6.50 6.50
0% 0%
-
EBIT (Operating Income) EBIT -127 -127
15% 15%
-
Net Profit -117 -117
16% 16%
-

In millions USD.

Don't miss a Thing! We will send you all news about Adicet Bio Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Adicet Bio Inc Stock News

Neutral
Business Wire
7 days ago
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial results and operational highlights for the third quarter ended September 30, 2025. “We were pleased to announce positive preliminary data last month from seve...
Neutral
Business Wire
12 days ago
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted inducement awards on October 31, 2025. Five individuals were hired by Adicet in October 2025. In the aggregate, Adicet granted new hires non-qualified stock...
Neutral
Business Wire
16 days ago
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Guggenheim 2nd Annual Healthcare Innovation Conference being held fr...
More Adicet Bio Inc News

Company Profile

resTORbio, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the development and commercialization of medicines for aging-related diseases and conditions. It offers an immunotherapy under the TORC1 program. The company was founded by Chen Schor and Joan Mannick on July 5, 2016 and is headquartered in Boston, MA.

Head office United States
CEO Chen Schor
Employees 152
Founded 2014
Website www.adicetbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today